582 related articles for article (PubMed ID: 27491640)
1. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.
Monjezi R; Miskey C; Gogishvili T; Schleef M; Schmeer M; Einsele H; Ivics Z; Hudecek M
Leukemia; 2017 Jan; 31(1):186-194. PubMed ID: 27491640
[TBL] [Abstract][Full Text] [Related]
2. Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.
Hudecek M; Gogishvili T; Monjezi R; Wegner J; Shankar R; Kruesemann C; Miskey C; Ivics Z; Schmeer M; Schleef M
Recent Results Cancer Res; 2016; 209():37-50. PubMed ID: 28101686
[TBL] [Abstract][Full Text] [Related]
3. Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview.
Prommersberger S; Monjezi R; Shankar R; Schmeer M; Hudecek M; Ivics Z; Schleef M
Methods Mol Biol; 2022; 2521():25-39. PubMed ID: 35732991
[TBL] [Abstract][Full Text] [Related]
4. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
[TBL] [Abstract][Full Text] [Related]
5. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
[TBL] [Abstract][Full Text] [Related]
6. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
Kebriaei P; Singh H; Huls MH; Figliola MJ; Bassett R; Olivares S; Jena B; Dawson MJ; Kumaresan PR; Su S; Maiti S; Dai J; Moriarity B; Forget MA; Senyukov V; Orozco A; Liu T; McCarty J; Jackson RN; Moyes JS; Rondon G; Qazilbash M; Ciurea S; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Kantarjian H; Keating M; Wierda W; Do KA; Largaespada DA; Lee DA; Hackett PB; Champlin RE; Cooper LJ
J Clin Invest; 2016 Sep; 126(9):3363-76. PubMed ID: 27482888
[TBL] [Abstract][Full Text] [Related]
7. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer.
Jin C; Fotaki G; Ramachandran M; Nilsson B; Essand M; Yu D
EMBO Mol Med; 2016 Jul; 8(7):702-11. PubMed ID: 27189167
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
[TBL] [Abstract][Full Text] [Related]
9. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.
Singh H; Huls H; Kebriaei P; Cooper LJ
Immunol Rev; 2014 Jan; 257(1):181-90. PubMed ID: 24329797
[TBL] [Abstract][Full Text] [Related]
10. Bacteria-free minicircle DNA system to generate integration-free CAR-T cells.
Cheng C; Tang N; Li J; Cao S; Zhang T; Wei X; Wang H
J Med Genet; 2019 Jan; 56(1):10-17. PubMed ID: 30030293
[TBL] [Abstract][Full Text] [Related]
11. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.
Magnani CF; Mezzanotte C; Cappuzzello C; Bardini M; Tettamanti S; Fazio G; Cooper LJN; Dastoli G; Cazzaniga G; Biondi A; Biagi E
Hum Gene Ther; 2018 May; 29(5):602-613. PubMed ID: 29641322
[TBL] [Abstract][Full Text] [Related]
13. Efficient Non-Viral T-Cell Engineering by Sleeping Beauty Minicircles Diminishing DNA Toxicity and miRNAs Silencing the Endogenous T-Cell Receptors.
Clauss J; Obenaus M; Miskey C; Ivics Z; Izsvák Z; Uckert W; Bunse M
Hum Gene Ther; 2018 May; 29(5):569-584. PubMed ID: 29562762
[TBL] [Abstract][Full Text] [Related]
14. Automated, scaled, transposon-based production of CAR T cells.
Lock D; Monjezi R; Brandes C; Bates S; Lennartz S; Teppert K; Gehrke L; Karasakalidou-Seidt R; Lukic T; Schmeer M; Schleef M; Werchau N; Eyrich M; Assenmacher M; Kaiser A; Prommersberger S; Schaser T; Hudecek M
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096530
[TBL] [Abstract][Full Text] [Related]
15. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC.
Ueda T; Kaneko S
Methods Mol Biol; 2019; 2048():85-91. PubMed ID: 31396933
[TBL] [Abstract][Full Text] [Related]
17. The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies.
Tsukahara T; Iwase N; Kawakami K; Iwasaki M; Yamamoto C; Ohmine K; Uchibori R; Teruya T; Ido H; Saga Y; Urabe M; Mizukami H; Kume A; Nakamura M; Brentjens R; Ozawa K
Gene Ther; 2015 Feb; 22(2):209-15. PubMed ID: 25427612
[TBL] [Abstract][Full Text] [Related]
18. Generation of CAR+ T Lymphocytes Using the Sleeping Beauty Transposon System.
Chicaybam L; Abdo L; Bonamino MH
Methods Mol Biol; 2020; 2086():131-137. PubMed ID: 31707672
[TBL] [Abstract][Full Text] [Related]
19. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
20. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.
Singh H; Srour SA; Milton DR; McCarty J; Dai C; Gaballa MR; Ammari M; Olivares S; Huls H; De Groot E; Marin D; Petropoulos D; Olson AL; Anderlini P; Im JS; Khouri I; Hosing CM; Rezvani K; Champlin RE; Shpall EJ; Cooper LJN; Kebriaei P
Front Immunol; 2022; 13():1032397. PubMed ID: 36439104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
